Healthcare of Ontario Pension Plan Trust Fund raised its position in RxSight, Inc. (NASDAQ:RXST – Free Report) by 761.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,131,400 shares of the company’s stock after buying an additional 1,000,000 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in RxSight were worth $6,969,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of RXST. Walleye Capital LLC boosted its position in shares of RxSight by 258.6% in the first quarter. Walleye Capital LLC now owns 314,616 shares of the company’s stock valued at $1,938,000 after acquiring an additional 226,871 shares during the period. Summit Securities Group LLC acquired a new stake in RxSight in the 1st quarter worth about $30,000. Rockefeller Capital Management L.P. raised its stake in RxSight by 27.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 23,848 shares of the company’s stock worth $248,000 after purchasing an additional 5,203 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in RxSight by 19.7% in the 4th quarter. Corient Private Wealth LLC now owns 36,095 shares of the company’s stock valued at $376,000 after purchasing an additional 5,933 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of RxSight by 511.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,249 shares of the company’s stock worth $44,000 after purchasing an additional 3,554 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.
RxSight Trading Up 1.3%
Shares of RxSight stock opened at $6.13 on Thursday. The company has a 50 day moving average of $5.27 and a 200-day moving average of $6.80. RxSight, Inc. has a 1-year low of $4.48 and a 1-year high of $13.22. The company has a market cap of $253.78 million, a PE ratio of -5.42 and a beta of 1.15.
Wall Street Analysts Forecast Growth
Read Our Latest Report on RXST
About RxSight
RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.
Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.
Recommended Stories
- Five stocks we like better than RxSight
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding RXST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RxSight, Inc. (NASDAQ:RXST – Free Report).
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
